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Abstract
Cranial dural arteriovenous fistula (cDAVF) may rarely lead to parkinsonism and rapid cogni-
tive decline. Dysfunction of the extrapyramidal system and the thalamus, due to venous con-
gestion of the Galenic system with subsequent parenchymal edema, is likely to represent an 
important pathophysiological mechanism. Here, we report a case of a 57-year-old man with 
a cDAVF of the straight sinus (Borden type III; DES-Zurich bridging vein shunt [BVS] type with 
direct, exclusive, and strained leptomeningeal venous drainage [LVD]) and subsequent edema 
of both thalami, the internal capsule, the hippocampi, the pallidum, and the mesencephalon. 
Several attempts at venous embolization were unsuccessful, and the neurological condition 
of the patient further deteriorated with progressive parkinsonism and intermittent episodes 
of loss of consciousness (KPS 30). A suboccipital mini-craniotomy was performed and the cul-
minal vein was disconnected from the medial tentorial sinus, achieving an immediate fistula 
occlusion. Three-month follow-up MRI revealed complete regression of the edema. Clinically, 
parkinsonism remitted completely, allowing for tapering of dopaminergic medication. His 
cognition markedly improved in further course. The purpose of this report is to highlight the 
importance of rapid and complete cDAVF occlusion to reverse venous hypertension and pre-
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vent progressive clinical impairment. The review of the literature underlines the high morbid-
ity and mortality of these patients. Microsurgical disconnection of the fistula plays an impor-
tant role in the management of these patients and, surprisingly, has not been reported so far.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
A cranial dural arteriovenous fistula (cDAVF) is an acquired vascular malformation char-
acterized by arteriovenous (AV) shunting within one of the following venous structures: the 
dural sinus (dural sinus shunt [DSS]), the transdural segment of the bridging veins (bridging 
vein shunt [BVS]), or the emissary and epidural veins (emissary vein shunt [EVS]) [1–3]. 
cDAVF represents approximately 10–15% of all intracranial AV malformations and has been 
described as being caused by traumatic injuries, venous sinus inflammation, brain surgery, 
and a hypercoagulable state [4], but the most plausible explanation of its development is 
sinus thrombosis, mostly as consequence of the previously listed conditions [2, 5].
The clinical manifestation of cDAVF depends on its anatomic location and the pattern of 
venous drainage. cDAVF with leptomeningeal venous drainage (LVD), also called cortical 
venous reflux, carries the highest risk of an aggressive clinical course and may present with 
venous congestion-related parenchymal edema, microbleeds, or massive hemorrhages, and 
subarachnoid bleeding due to the rupture of venous varcies [6]. Borden et al. [4] classified 
these lesions as type 2 and type 3. Cognard et al. [7] described them as type IIb, IIa + IIb, III, 
IV, and V. According to the DES (direct, exclusive, strained)-Zurich classification, LVD is an 
inherent characteristic of all BVS-type fistulae. Due to their specific venous angioachitecture, 
DSS-type fistulae and EVS present with LVD frequently and infrequently, respectively 
[2, 3, 6].
A rare, but severe consequence of cDAVF at a specific location is the occurrence of parkin-
sonism with/or without progressive cognitive decline. Parkinsonism as a clinical manifes-
tation of cDAVF is exceptionally rare and has only been reported in case reports (Table 1) 
[8–26]. Dysregulation of the extrapyramidal system and the thalamus due to venous congestion 
of the Galenic system, with subsequent parenchymal edema, seems to represent an important 
pathophysiological mechanism here [20].
The early diagnosis and prompt treatment of cDAVF with LVD is mandatory to reverse 
the venous congestion and eliminate the risk of bleeding [4]. Complete occlusion of the cDAVF 
is obligatory to achieve neurological recovery and needs to be urgently performed. However, 
the incidence of incomplete cDAVF occlusion in these patients, which leads to further neuro-
logical deterioration, and even death, is surprisingly high in the literature [11, 12, 14, 22, 
24, 25].
The rare incidence of cDAVF leading to parkinsonism and cognitive dysfunction and the 
challenging treatment prompted us to report this case and discuss the current management 
of cranial cDAVF based on a literature review.
Case Report
A 57-year-old man presented to an external hospital due to rapidly progressive cognitive 
impairment over 3 months. Neurological examination revealed an altered mental status, with 
impaired executive function and a hypokinetic movement disorder with gait impairment, 
hypophonia, and hypomimia. The patient had known reflux esophagitis but no other signif-
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icant medical history. After unspecific cranial computed tomography (CT) and cerebrospinal 
fluid examination, cranial magnetic resonance imaging (MRI) revealed partial thrombosis of 
the straight sinus with diffuse edema of both thalami, the internal capsule, the hippocampi, 
the pallidum, and the base of the mesencephalon (right > left) as well as multiple microbleeds 
in the basal ganglia and dilated deep cerebral veins.
Digital subtraction angiography (DSA) was performed, which showed a typical DAVF at 
the level of the thrombosed part of the straight sinus. The fistula was fed by the tentorial dural 
arteries and drained through the straight sinus into the median tentorial sinus, supraculminal 
vein, superior vermian vein, and the system of the vein of Galen. Due to the thrombosis of the 
proximal segment of the straight sinus, missing direct outflow, and arterialization of the 
system of the vein of Galen with consecutive flow reversion, the fistula caused severe reflux 
and congestion in the system of the internal cerebral veins (Fig. 1a, b). It was thus classified 
as Cognard type III, Borden type III, and DES-Zurich BVS type with direct, exclusive, and 
strained LVD (Fig. 1).
At an external hospital, several attempts at venous embolization of the fistula were not 
successful. Transarterial embolization was not performed due to high-grade outlet stenosis 
of the left vertebral artery. A transarterial embolization attempt via the transosseous-supplied 
posterior meningeal artery did not seem promising and was therefore not attempted. The 
patient was referred to our department 6 weeks after initial presentation.
At the time of admission, the patient showed severe neurological impairment and was 
not able to take care of himself, requiring considerable assistance and frequent medical care 
(Karnofsky performance score [KPS] of 30).
Repeated MRI and magnetic resonance angiography (MRA) revealed a massive 












Fig. 1. a DSA reveals an arteriovenous shunt (arrow) at the level of the thrombosed part of the straight sinus. 
b Graphic illustration of the cDAVF. The fistula is fed by the tentorial dural arteries (red) and drains through 
the straight sinus into the median tentorial sinus, supraculminal vein, superior vermian vein, and then into 
the system of the vein of Galen. Due to the thrombosis (asterisk) of the proximal segment of the straight sinus, 
missing direct outflow, and arterialization of the system of the vein of Galen with consecutive flow reversion, 
the fistula causes severe reflux and congestion in the system of the internal cerebral veins. The cDAVF is clas-
sified as Cognard type III, Borden type III, and DES-Zurich bridging vein shunt type with direct, exclusive, and 
strained LVD. SSS, superior sagittal sinus.
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campi, the pallidum, and the mesencephalon, predominantly on the right side, due to the 
nonoccluded cDAVF (Fig. 2a, b), and also multiple microhemorrhages within the congested 
tissue (Fig. 2c).
A suboccipital paramedian right-sided mini-craniotomy was performed. Microsur-
gical opening of the cisterna magna was performed to facilitate supracerebellar infraten-
torial access and to identify the fistula draining into the supraculminal and superior 
vermian veins. Verification of its arterialization was done by fluorescein angiography. The 
culminal vein was disconnected from the medial tentorial sinus by bipolar electrocoagu-
lation, achieving an immediate fistula occlusion. Verification of the successful discon-
nection was also done by fluorescein angiography. Postoperative MRA and DSA showed 
complete obliteration of the cDAVF (Fig. 3b, d). During hospitalization, a detailed exami-
nation of thrombophilia was performed due to the unexplained thrombosis of the straight 
sinus. There was no evidence of thrombophilia or oncological disease. At discharge, 12 
days after surgery, the patient showed a significantly improved general condition. He was, 
however, not able to walk by himself and his cognitive impairment was still severe (a KPS 
of 60).
Carbidopa/levodopa was started based on the diagnosis of a secondary akinetic rigid 
Parkinson syndrome, and the neurological condition of the patient further improved. In the 
further course of the treatment, the dose was increased and ropinirole was added so that the 
patient was free of Parkinson symptoms when he left the rehabilitation clinic.
Three months later, the patient presented at our outpatient clinic in a significantly 
improved clinical condition (a KPS of 80–90). There were no signs of parkinsonism and his 
cognitive condition had improved. MRI showed complete regression of the bithalamic edema, 
internal capsule, hippocampi, pallidum, and mesencephalon (Fig. 4b, d), although the throm-
bosis of the straight sinus had remained unchanged.
Due to the complete regression of the venous stasis edema and the working diagnosis of 
a secondary Parkinson syndrome, dopaminergic medication was slowly tapered with no 





Fig. 2. a, b Sagittal and axial section of FLAIR-weighted images show a massive progression of the venous 
congestive edema of both thalami, internal capsule, pallidum and mesencephalon due to the nonoccluded 
cDAVF. c SWI-weighted images show multiple microhemorrhages within the congested tissue.
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Discussion
We present here the case of a 57-year-old male with a cDAVF of the straight sinus (Borden 
type III, Cognard type III, DES – Zurich BVS-type with direct, exclusive, and strained LVD) and 
worsening venous congestion of the Galenic system. He presented clinically with executive 
dysfunction, cognitive impairment, and disorientation. After complete microsurgical fistula 
occlusion, the bithalamic edema (with involvement of the internal capsule, hippocampi, and 
mesecencephalon) regressed. Concomitantly, parkinsonism disappeared and his functional 
impairment improved significantly. 
Parkinsonism as a clinical manifestation of cDAVF is exceptionally rare and has so far 
only been reported in case reports and small case series [27]. We identified 24 cases described 
as having cDAVF and associated parkinsonism in the literature (Table 1). AV shunting into 
the transverse and sigmoid sinuses (n = 14; 58.3%) was most often described, followed by 
the superior sagittal sinus (n = 3; 12.5%), the torcular, straight sinus, and multiple sinus 
involvement (each n = 2; 8.3%), and anterior cranial fossa (n = 1; 4.2%). Retrograde filling of 






Fig. 3. Sagittal section of T1-weighted MRI TOF with gadolinium before (a) and after microsurgical clipping 
and complete cDAVF occlusion (b). DSA before (c) and after complete cDAVF occlusion (d).
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described in 16 patients (66.6%). Limited data or no data on the venous reflux were provided 
for 8 patients (33.3%).
Lee et al. [20] were the first to propose the theory of basal ganglia dysfunction due to 
impaired drainage of the deep internal veins in patients with cDAVF and parkinsonism. They 
a b
c d
Fig. 4. Sagittal section of FLAIR (a, b) and axial section of T2-weighted (c, d) MRI. The 3-month follow-up 
MRI displays complete regression of the venous congestion of the Galenic system (b, d) compared to preop-
eratively (a, b).
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described a 60-year-old patient with cDAVF of the left sigmoid sinus with retrograde filling 
of the deep venous system, and superior sagittal sinus with prominent cortical venous reflux 
[20]. The patient showed reversible parkinsonism after embolization, which was well corre-
lated with an increase in the basal ganglia-cerebellar perfusion ratio on SPECT, suggesting 
that a perfusion defect was responsible for the pathogenesis of the parkinsonism [20].
Kim et al. [15] reported a patient with decreased 18F-FP-CIT uptake in cDAVF-associated 
parkinsonism. They suggested that hemodynamic impairment could cause parkinsonism via 
an accentuation of the underlying dopamine deficiency in subjects with preclinical-stage 
parkinsonism. The parkinsonism in their patient improved following the endovascular 
occlusion of the cDAVF without antiparkinson drug therapy [15].
In our case, both the presynaptic dopaminergic neurons in the mesencephalon and the 
postsynaptic neurons in the striatum, essential to mediate the treatment effect of dopami-
nergic medication, were affected by the edema (Fig. 2a, b). In addition, given the fact that 
carbidopa/levodopa was started during the process of neurological improvement, it remains 
unclear if the first signs of improvement during rehabilitation were related to this dopami-
nergic medication or to surgery. We believe it is more likely that the microsurgical discon-
nection of the cDAVF was primarily responsible for the clinical improvement during reha-
bilitation. The medication could therefore be tapered later without symptom recurrence. In 
the literature review, it was found that dopaminergic medication did not lead to improvement 
in 4 patients [13, 17, 20, 24] and that a transient response was reported in 3 patients [12, 16].
Treatment of patients with cDAVF and LVD in the deep venous system with secondary 
parkinsonism and/or cognitive impairment is challenging, as a remission of symptoms has 
been described in only a few cases in which complete fistula occlusion was achieved. The 
literature review illustrates the severe natural history of cDAVF; 2 patients died (no inter-
vention), and 3 patients showed severe neurological deterioration (1 had no intervention and 
2 attempted unsuccessful embolization). These numbers might even be underestimated due 
to limited data on follow-up in the cases described and the known general bias against 
reporting poor results [9, 11, 12, 24]. 
Our aim is to highlight the importance of rapid diagnosis and complete occlusion of the 
cDAVF to reverse parkinsonism and prevent further neurological deterioration, including 
death. Interestingly, complete cDAVF occlusion was achieved in only 8 of 24 (33.3%) and 
incomplete occlusion in 5 patients (20.8%). In 3 patients (12.5%), no intervention was made; 
insufficient data were available for 8/24 (33.3%) (Table 1). In all the reported cases, endo-
vascular embolization was the 1st treatment choice. In 3 cases, no intervention was performed; 
in 1 case, no information was available about the treatment used. Surprisingly, no cDAVF in 
this literature review was treated by microsurgical cDAVF disconnection, despite complete 
occlusion being achieved in only 8/24 (33.3%) patients. Endovascular embolization was 
repeated in a few cases when the first attempt was unsuccessful (Table 1). In 3 cases, a 
combined endovascular and surgical approach was performed to gain access to the cDAVF for 
endovascular treatment, but microsurgical clipping/disconnection of the cDAVF was not 
performed in these cases (Table 1) [17, 18, 23]. 
Even in cases where only incomplete cDAVF occlusion was achieved through endovas-
cular embolization, a “watch-and-wait-strategy” was the preferred strategy, exposing the 
patient to persistent LVD and the risk of clinical deterioration. 
The detailed understanding of the angioarchitecture of the cDAVF is essential to determine 
the treatment strategy. It is based on the precise identification of the AV shunt localization 
(BVS, DSS, or EVS) as well as on the understanding of the LVD. A detailed review of the angio-
architecture of cDAVF is beyond the scope of this report and we refer the interested reader 
to the description by Baltsavias and Valavanis [1–3, 6]. To achieve complete cDAVF occlusion, 
a multidisciplinary discussion of the endovascular and microsurgical options is recom-
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mended. Although we favor endovascular surgery as the first-line treatment, microsurgery 
should be considered in cases of persistence of an AV shunt. The surgical approach is often 
straightforward and can be easily performed by an experienced vascular neurosurgeon. 
Despite a preoperatively detailed understanding of the angioarchitecture of the cDAVF, intra-
operative identification of the AV shunt might pose a challenge; confirmation of the AV shunt 
as well as the successful disconnection should therefore be verified by intraoperative fluo-
rescein angiography [28].
Patients with cDAVF diagnosed as BVS, the majority of which are Borden type III, are 
excellent candidates for primary microsurgical cDAVF occlusion [29]. The surgical approach 
is straightforward and can be done through a simple mini-craniotomy by simply discon-
necting the draining vein, regardless of the presence or absence of venous strain [29]. 
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